Get the Stockscreener App
1.9055
1.29%
-0.0295
Caribou Biosciences Inc stock is traded at $1.9055, with a volume of 52,689.
It is down -1.29% in the last 24 hours and down -12.79% over the past month.
Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) biopharmaceutical company dedicated to transforming the lives of patients with devastating diseases by applying its novel CRISPR platform, CRISPR hybrid RNA-DNA (chRDNA), toward the development of next-generation, genome-edited cell therapies. The company operates and manage business as one reportable operating segment, which is the business of developing a pipeline of allogeneic CAR-T and CAR-NK cell therapies. Geographically, it operates in United States and Rest of the World, of which United States derives maximum revenue.
See More
Previous Close:
$1.935
Open:
$1.93
24h Volume:
52,689
Relative Volume:
0.02
Market Cap:
$178.45M
Revenue:
$34.48M
Net Income/Loss:
$-102.07M
P/E Ratio:
-1.3051
EPS:
-1.46
Net Cash Flow:
$-104.90M
1W Performance:
-1.55%
1M Performance:
-12.79%
6M Performance:
+75.23%
1Y Performance:
-3.05%
1-Day Range:
$1.90
$1.95
1-Week Range:
$1.745
$1.965
52-Week Range:
$0.66
$3.535
Caribou Biosciences Inc Stock (CRBU) Company Profile
Name
Caribou Biosciences Inc
Sector
Industry
Phone
510-982-6030
Address
2929 7TH STREET, SUITE 105, BERKELEY
Compare CRBU with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CRBU
Caribou Biosciences Inc
|
1.9092 | 181.33M | 34.48M | -102.07M | -104.90M | -1.46 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.20 | 116.04B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
730.81 | 75.97B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
467.51 | 61.48B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
913.71 | 56.40B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
205.82 | 43.73B | 447.02M | -1.18B | -906.14M | -6.1812 |
Caribou Biosciences Inc Stock (CRBU) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-03-24 | Downgrade | Evercore ISI | Outperform → In-line |
| Nov-08-23 | Initiated | Cantor Fitzgerald | Neutral |
| Oct-31-23 | Initiated | Evercore ISI | Outperform |
| Jul-11-23 | Initiated | Truist | Buy |
| Feb-18-22 | Initiated | RBC Capital Mkts | Outperform |
| Dec-01-21 | Initiated | Oppenheimer | Outperform |
| Nov-30-21 | Initiated | H.C. Wainwright | Buy |
| Nov-15-21 | Upgrade | Citigroup | Neutral → Buy |
| Aug-17-21 | Initiated | BofA Securities | Buy |
| Aug-17-21 | Initiated | Citigroup | Neutral |
| Aug-17-21 | Initiated | SVB Leerink | Outperform |
View All
Caribou Biosciences Inc Stock (CRBU) Latest News
Will Caribou Biosciences Inc. stock reach Wall Street targets2025 Stock Rankings & Free AI Powered Buy and Sell Recommendations - Newser
Caribou Biosciences Target of Unusually Large Options Trading (NASDAQ:CRBU) - MarketBeat
Caribou Biosciences to Host Expert Panel on Access Expansion for vispa-cel CAR-T Therapy at ASH Annual Meeting - Quiver Quantitative
Caribou Biosciences to Host In-Person and Virtual KOL Event at ASH 2025 - Yahoo Finance
MACD Signal: Will ABEV stock outperform value stocksJuly 2025 Earnings & Accurate Intraday Trading Signals - BỘ NỘI VỤ
Earnings Risk: What analyst consensus says on Caribou Biosciences Inc stockJuly 2025 Pullbacks & Free Daily Entry Point Trade Alerts - BỘ NỘI VỤ
Caribou Biosciences CEO to address Evercore Healthcare Conference - Traders Union
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Aga - The National Law Review
Caribou Biosciences signals access challenge in CAR-T cell therapy - Traders Union
Analyzing Caribou Biosciences Inc. with multi timeframe chartsJuly 2025 WrapUp & Accurate Trade Setup Notifications - newser.com
Is Caribou Biosciences Inc. stock positioned well for digital economyJuly 2025 Intraday Action & Long-Term Safe Investment Plans - newser.com
Is it time to cut losses on Caribou Biosciences Inc.Rate Hike & Verified Momentum Stock Watchlist - newser.com
Can Caribou Biosciences Inc. stock maintain operating margins - newser.com
Is Caribou Biosciences Inc. stock a contrarian buyEarnings Recap Summary & AI Driven Stock Price Forecasts - newser.com
Risk adjusted return profile for Caribou Biosciences Inc. analyzedMarket Activity Recap & Daily Volume Surge Signals - newser.com
Exit strategy if you’re trapped in Caribou Biosciences Inc.2025 Buyback Activity & Expert Curated Trade Setup Alerts - newser.com
How to build a custom watchlist for Caribou Biosciences Inc.Quarterly Market Summary & Stepwise Swing Trade Plans - newser.com
Alert wrongly tagged to Caribou Biosciences withdrawn - MarketScreener
Caribou Biosciences (CRBU) Price Target Increased by 25.61% to 11.35 - Nasdaq
Using flow based indicators on Caribou Biosciences Inc.July 2025 Setups & AI Forecast Swing Trade Picks - newser.com
Statistical indicators supporting Caribou Biosciences Inc.’s strength2025 Sector Review & Safe Entry Zone Tips - newser.com
Will Caribou Biosciences Inc. stock go up soonDollar Strength & Safe Capital Growth Trade Ideas - newser.com
Comparing Caribou Biosciences Inc. in custom built stock radarsJuly 2025 Catalysts & Community Verified Swing Trade Signals - newser.com
Published on: 2025-11-15 04:00:26 - newser.com
Why Caribou Biosciences Inc. stock remains on buy lists2025 Volume Leaders & Accurate Technical Buy Alerts - newser.com
Caribou Biosciences reveals new data on CAR-T supply chain strategies - Traders Union
How interest rate cuts could boost Caribou Biosciences Inc. stockQuarterly Portfolio Summary & High Accuracy Swing Trade Signals - Fundação Cultural do Pará
Ranking Caribou Biosciences Inc. among high performing stocks via tools2025 Breakouts & Breakdowns & Reliable Volume Spike Trade Alerts - newser.com
What machine learning models say about Caribou Biosciences Inc.July 2025 Trade Ideas & Verified Entry Point Detection - newser.com
Caribou Biosciences Narrows Losses And Wins Wall Street’s Favor - Finimize
Caribou Biosciences Inc Stock (CRBU) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.46%
1.57%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):